EOM Pharmaceuticals is focused on developing innovative immunomodulators, particularly their lead drug candidate, EOM613. This investigational agent is a peptide-nucleic acid solution designed to act dynamically on both pro-inflammatory and anti-inflammatory cytokines, making it a broad-spectrum immune regulator. EOM613 has demonstrated the ability to modulate immune responses by either suppressing or stimulating key immune cells, such as monocytes and macrophages, depending on their activation state. This unique "dynamic dual action" allows EOM613 to potentially mitigate hyperimmune reactions, such as cytokine storms, while also maintaining necessary immune functions, which is a significant advancement over traditional immunomodulators that primarily reduce inflammation.

In addition to EOM613, EOM Pharmaceuticals is developing EOM147, a broad-spectrum aminosterol aimed at treating retinal diseases. EOM147 operates through a distinct intracellular mechanism that influences multiple angiogenic growth factors, differentiating it from existing therapies that typically target only one factor, such as VEGF. This investigational drug is being formulated as an eye drop, representing a potential breakthrough in treatment delivery that avoids the need for intraocular injections. EOM147 is currently in the planning stages for Phase 2 clinical trials, targeting conditions like diabetic retinopathy and age-related macular degeneration, further showcasing EOM Pharmaceuticals' commitment to advancing therapeutic options in challenging medical areas.

United States

Powering relentless science by developing and commercializing first-in-class treatments to address debilitating and potentially fatal diseases, including COVID-19 and other infectious diseases; autoimmune diseases including rheumatoid arthritis; cachexia associated with AIDS or cancer; and topical non-invasive treatments for sight-robbing retinal diseases.

EOM Pharmaceuticals

Company Details